Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Nov 6, 2018

FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 1, 2018

Provention Bio to Report Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 8, 2018
Oct 31, 2018

Sanofi Q3 2018 Performance Confirms Return to Growth
- Photos 4
Oct 30, 2018

FDA grants priority review for Sanofi's dengue vaccine candidate
Oct 23, 2018

Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis

- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.